Skip to main content

HER-2/neu, Serum

CPT 83950
Synonyms
  • HER-2 Extracellular Domain (ECD)
  • HER-2/neu Shed Antigen

Test Details

Methodology

Immunochemiluminometric (ICMA)

Result Turnaround Time

5 days

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Related Documents

Use

This test is used for the quantitative measure of HER-2/neu in human serum. HER-2/neu values obtained may be used in the follow-up and monitoring of patients with metastatic breast cancer. HER-2/neu values should be used in conjunction with information available from clinical and other diagnostic procedures in the management of breast cancer. The clinical utility of the measurement of HER-2/neu as a prognostic indicator for early recurrence and in the management of patients on immunotherapy regimens has not been fully established.

Limitations

Elevated levels of serum HER-2/neu are observed in a subset of patients with HER-2/neu-positive tumors. Approximately 25% to 30% of breast cancers demonstrate overexpression of the HER-2/neu protein.

Specimen Requirements

Specimen

Serum, frozen

Volume

1 mL

Minimum Volume

0.2 mL

Container

Red-top tube or gel-barrier tube

Collection Instructions

Transfer serum to screw-cap tube for shipping. Freeze specimen at -20°C and ship on dry ice. To avoid delays in turnaround time when requesting multiple tests on frozen samples, please submit separate frozen specimens for each test requested.

Storage Instructions

Freeze

Causes for Rejection

Hemolysis; defrosted or freeze-thawed specimen

References

Fehm T, Maimonis P, Weitz S, Teramoto Y, Katalinic A, Jäger W. Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res Treat. 1997 Mar; 43(1):87-95. 9065602
Molina R, Jo J, Filella X, et al. C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis. Anticancer Res. 1996 Jul-Aug; 16(4B):2295-2300.8694559

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
480136 HER-2/neu, Serum 480134 Her-2/neu, Serum ng/mL 42914-2
480136 HER-2/neu, Serum 511958 PDF 80563-0
Order Code480136
Order Code NameHER-2/neu, Serum
Order Loinc
Result Code480134
Result Code NameHer-2/neu, Serum
UofMng/mL
Result LOINC42914-2
Order Code480136
Order Code NameHER-2/neu, Serum
Order Loinc
Result Code511958
Result Code NamePDF
UofM
Result LOINC80563-0